A long­time Lau­ra Shawver fan calls the se­r­i­al en­tre­pre­neur back to the helm of a biotech up­start

6 years ago
People
Startups

‘Break­through’ drugs in­clud­ed on Roche’s list of PhII/III stud­ies axed in Q1 — with piv­otal Mir­ros tri­al on ...

6 years ago
R&D

First NDA in. Re­gion­al deal done. Now My­ovant has PhI­II da­ta to back up re­l­u­golix's push to an­oth­er block­buster ...

6 years ago
R&D

Bio­gen push­es back its time­line on the big ad­u­canum­ab FDA fil­ing as Covid-19 slows work — shares wilt

6 years ago
R&D

Covid-19 roundup: Carl June on hav­ing Covid-19 and his plan to treat it; NIH preach­es cau­tion; 2 new vac­cines en­ter ...

6 years ago
Coronavirus

Ab­b­Vie, J&J block­buster Im­bru­vi­ca rakes in 11th FDA ap­proval, as com­peti­tors work on erod­ing fran­chise

6 years ago
R&D
Pharma

Amid remde­sivir craze Gilead finds time for an­oth­er on­col­o­gy pact — loop­ing in all things NK cells

6 years ago
Deals

BAR­DA chief leaves po­si­tion as agency en­ters un­prece­dent­ed vac­cine cam­paign, rais­ing ques­tions about fed­er­al Covid-19 ...

6 years ago
People
Coronavirus

VA study spot­lights high­er death rate among Covid-19 pa­tients treat­ed with the con­tro­ver­sial drug hy­drox­y­chloro­quine

6 years ago
R&D
Coronavirus

Sang­amo ties up with a new­com­er in the cell ther­a­py field; Lab­Corp wins FDA au­tho­riza­tion of lat­est Covid-19 test

6 years ago
News Briefing

More pos­i­tive PhI­II da­ta set stage for Scynex­is' vagi­nal yeast in­fec­tion drug ap­proval

6 years ago
R&D

Astel­las snaps up mi­to­chon­dria-fo­cused biotech, beefs up drug dis­cov­ery in bud­get deal

6 years ago
Deals

Mer­ck KGaA adds to gene ther­a­py man­u­fac­tur­ing boom with €100M fa­cil­i­ty in Cal­i­for­nia

6 years ago
Cell/Gene Tx

Short at­tack tar­gets one of the fa­vorites now shar­ing the lead in the pop­u­lar KRAS drug de­vel­op­ment race

6 years ago
R&D

EMA up­dates on reg­u­la­to­ry ex­pec­ta­tions amid Covid-19

6 years ago
FDA+
Coronavirus

Data­vant boots up a big Covid-19 reg­istry — look­ing to shine a light on virus spread, im­pact and most ef­fec­tive ...

6 years ago
R&D
Coronavirus

An­oth­er PhI­II win in hand, Cara aims straight for pri­or­i­ty re­view of 'break­through' pru­ri­tus drug

6 years ago
R&D

Covid-19 roundup: The pan­dem­ic bear — You think a vac­cine and herd im­mu­ni­ty are just months away? Dream on, says ...

6 years ago
Coronavirus

Still no ad­u­canum­ab fil­ing and an in-house gath­er­ing trig­gered a health dis­as­ter, but Bio­gen's CEO nev­er­the­less took ...

6 years ago
People

Es­pe­ri­on strikes Japan deal for 'goldilock­s' cho­les­terol drug, bags $60M cash as pan­dem­ic forces vir­tu­al US roll­out

6 years ago
Deals

Sofinno­va Telethon Fund backs Nal­dini's gene ther­a­py biotech; ORIC prices $75M IPO

6 years ago
News Briefing

Piv­otal da­ta sug­gest clean safe­ty pro­file, po­ten­cy could set Idor­si­a's sleep­ing pill apart

6 years ago
R&D

Ex­elix­is lands PhI­II kid­ney can­cer win with Bris­tol My­ers in their hunt for $4 bil­lion

6 years ago
R&D

It’s not the mon­ey: The lat­est For­tune list of the top 10 bio­phar­mas to work for in­cludes a few sur­prise play­ers

6 years ago
People
First page Previous page 834835836837838839840 Next page Last page
A service from the Financial Times